Difference between mounjaro & zepbound

The short version: Mounjaro and Zepbound are the exact same drug, tirzepatide, sold under two brand names for two different FDA-approved indications.

Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in obesity. The molecule, the dose, the pen, and the manufacturer (Eli Lilly) are identical. The only difference is the label on the box and what the doctor writes the prescription for. This is a common regulatory strategy: a single drug gets two brand names so it can be marketed separately for each condition, often at different prices.

The evidence for tirzepatide comes almost entirely from manufacturer-funded trials. The SURPASS program (diabetes) and SURMOUNT program (obesity) are large, well-run randomized trials. In SURMOUNT-1, people without diabetes lost 16.5% to 22.4% of their body weight over 72 weeks on the highest dose, compared to 3.1% on placebo [1]. The SURPASS-CVOT trial, which compared tirzepatide to another drug (dulaglutide) in 13,299 people with diabetes and heart disease, found a 16% reduction in a broad cardiorenal endpoint, driven mostly by fewer deaths and heart attacks [8]. These are real clinical outcomes, not just lab values.

What the evidence does not cover is long-term safety beyond a few years. The trials run 1-2 years. The gastrointestinal side effects are common and dose-dependent: nausea in 14-60% of people, and about 6-7% of people on the highest doses stop the drug because of them [7, 14]. The drug also raises heart rate by about 5-7 beats per minute and causes arrhythmias in a small subset [7]. Whether these effects matter over a decade of use is unknown, because the studies do not exist.

My call: for someone with obesity or diabetes who understands the gastrointestinal side effects and accepts that the long-term safety data is thin, tirzepatide is the most effective weight-loss drug on the market. The two brand names are a pricing and marketing distinction, not a medical one. Confidence: high on efficacy, moderate on long-term safety.